CN102078310B - 大体线性的泡腾口服芬太尼剂型和施用方法 - Google Patents
大体线性的泡腾口服芬太尼剂型和施用方法 Download PDFInfo
- Publication number
- CN102078310B CN102078310B CN2011100059711A CN201110005971A CN102078310B CN 102078310 B CN102078310 B CN 102078310B CN 2011100059711 A CN2011100059711 A CN 2011100059711A CN 201110005971 A CN201110005971 A CN 201110005971A CN 102078310 B CN102078310 B CN 102078310B
- Authority
- CN
- China
- Prior art keywords
- fentanyl
- dosage form
- dose
- cmax
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 title claims abstract description 209
- 229960002428 fentanyl Drugs 0.000 title claims abstract description 178
- 239000002552 dosage form Substances 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title abstract description 34
- 238000011282 treatment Methods 0.000 claims description 130
- 239000000126 substance Substances 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 27
- 229930195725 Mannitol Natural products 0.000 claims description 26
- 239000000594 mannitol Substances 0.000 claims description 26
- 235000010355 mannitol Nutrition 0.000 claims description 26
- 208000002193 Pain Diseases 0.000 claims description 24
- 230000036407 pain Effects 0.000 claims description 24
- 239000012458 free base Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 208000000003 Breakthrough pain Diseases 0.000 claims description 11
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 9
- 229960001021 lactose monohydrate Drugs 0.000 claims description 9
- 239000007891 compressed tablet Substances 0.000 claims description 8
- 229940071117 starch glycolate Drugs 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 235000007983 food acid Nutrition 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 238000010979 pH adjustment Methods 0.000 claims 2
- 125000005587 carbonate group Chemical group 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 78
- 238000009472 formulation Methods 0.000 abstract description 72
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 description 102
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 72
- 229960004207 fentanyl citrate Drugs 0.000 description 71
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 37
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 32
- 229940079593 drug Drugs 0.000 description 30
- 210000000214 mouth Anatomy 0.000 description 29
- 229940060201 actiq Drugs 0.000 description 27
- 239000000945 filler Substances 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 239000007884 disintegrant Substances 0.000 description 22
- 239000008109 sodium starch glycolate Substances 0.000 description 21
- 229940079832 sodium starch glycolate Drugs 0.000 description 21
- 229920003109 sodium starch glycolate Polymers 0.000 description 21
- 235000019359 magnesium stearate Nutrition 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- 235000017550 sodium carbonate Nutrition 0.000 description 15
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 229960004106 citric acid Drugs 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 230000007794 irritation Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000001694 spray drying Methods 0.000 description 11
- 241000070918 Cima Species 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 229940127240 opiate Drugs 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000007907 direct compression Methods 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 229960003086 naltrexone Drugs 0.000 description 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- 206010038678 Respiratory depression Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011475 lollipops Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037237 body shape Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011551 log transformation method Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 238000002106 pulse oximetry Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
- 101100042265 Caenorhabditis elegans sem-2 gene Proteins 0.000 description 1
- 101100371857 Caenorhabditis elegans unc-71 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009642 citrate test Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006103 coloring component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940100629 oral lozenge Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53361903P | 2003-12-31 | 2003-12-31 | |
| US60/533,619 | 2003-12-31 | ||
| US61566504P | 2004-10-04 | 2004-10-04 | |
| US60/615,665 | 2004-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800394845A Division CN1901890B (zh) | 2003-12-31 | 2004-12-30 | 大体线性的泡腾口服芬太尼剂型和施用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102078310A CN102078310A (zh) | 2011-06-01 |
| CN102078310B true CN102078310B (zh) | 2013-01-23 |
Family
ID=34753002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100059711A Expired - Lifetime CN102078310B (zh) | 2003-12-31 | 2004-12-30 | 大体线性的泡腾口服芬太尼剂型和施用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7862832B2 (https=) |
| EP (1) | EP1708686B1 (https=) |
| JP (2) | JP2007517054A (https=) |
| KR (1) | KR101184138B1 (https=) |
| CN (1) | CN102078310B (https=) |
| AT (1) | ATE498395T1 (https=) |
| AU (1) | AU2004311880B2 (https=) |
| BR (1) | BRPI0418228B8 (https=) |
| CA (1) | CA2548915C (https=) |
| CY (1) | CY1111458T1 (https=) |
| DE (1) | DE602004031462D1 (https=) |
| DK (1) | DK1708686T3 (https=) |
| EA (1) | EA010826B1 (https=) |
| HR (1) | HRP20110336T1 (https=) |
| IL (1) | IL176449A (https=) |
| ME (1) | ME01300B (https=) |
| NO (1) | NO338714B1 (https=) |
| NZ (1) | NZ548216A (https=) |
| PL (1) | PL1708686T3 (https=) |
| PT (1) | PT1708686E (https=) |
| RS (1) | RS51713B (https=) |
| WO (1) | WO2005065319A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
| US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US7862833B2 (en) * | 2003-12-31 | 2011-01-04 | Cima Labs, Inc. | Effervescent oral opiate dosage forms and methods of administering opiates |
| CN102078310B (zh) | 2003-12-31 | 2013-01-23 | 奇马实验室公司 | 大体线性的泡腾口服芬太尼剂型和施用方法 |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| EP1715853A4 (en) | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
| US20070123562A1 (en) * | 2005-05-25 | 2007-05-31 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the-night insomnia |
| US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| US20070020186A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| US20070104763A1 (en) * | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| US20080090874A1 (en) * | 2006-09-20 | 2008-04-17 | Messina John C Jr | Treatment of breakthrough pain in patients suffering from chronic low back pain |
| US20080132535A1 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized Zolpidem Pharmaceutical Compositions |
| BRPI0719428A2 (pt) * | 2006-12-01 | 2014-02-25 | Cima Labs Inc | Forma de dosagem transmucosal oral sólida, método para tratar dependência de nicotina em um receptor que deseja tal tratamento, sistema de distribuição de nicotina transmucosal oral, e, método de substituíção de nicotina. |
| US20090214442A1 (en) * | 2006-12-01 | 2009-08-27 | Cephalon, Inc. | Oral Transmucosal Nicotine Dosage Form |
| CA2677281C (en) * | 2007-02-09 | 2019-10-29 | Durect Corporation | Transoral dosage forms comprising sufentanil and naloxone |
| US20080287494A1 (en) * | 2007-04-24 | 2008-11-20 | Cephalon, Inc. | Transmucosal treatment methods in patients with mucositis |
| NZ580967A (en) | 2007-05-01 | 2012-04-27 | Cephalon Inc | Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides |
| EP2604257B1 (en) * | 2007-08-07 | 2017-06-28 | Acelrx Pharmaceuticals, Inc. | Oral transmucosal dosage forms comprising sufentanil and triazolam |
| ITMI20071971A1 (it) * | 2007-10-10 | 2009-04-11 | Altergon Sa | Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| KR101751906B1 (ko) | 2009-03-04 | 2017-06-29 | 엠플리큐어 아베 | 새로운 오용 방지 배합물 |
| EP2427177B1 (en) * | 2009-05-08 | 2018-03-28 | Emplicure AB | Composition for sustained drug delivery comprising geopolymeric binder |
| CA2798702A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholresistant metoprolol-containing extended-release oral dosage forms |
| NO2613784T3 (https=) | 2010-09-07 | 2018-05-12 | ||
| US9320526B1 (en) * | 2011-10-13 | 2016-04-26 | Enteroptyx | Punctum plug |
| EP3150199B1 (en) | 2012-05-02 | 2018-08-08 | Orexo AB | New alfentanil composition for the treatment of acute pain |
| CN105407925A (zh) * | 2013-03-15 | 2016-03-16 | 迈兰公司 | 用于泡腾剂型的制造工艺 |
| NZ732808A (en) | 2014-12-23 | 2021-12-24 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
| NO20171457A1 (no) * | 2016-12-20 | 2018-06-21 | X Ing As | Effervesent sugetablett |
| WO2018117855A1 (en) * | 2016-12-20 | 2018-06-28 | X-Ing As | Effervescent lozenge |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1262888A (en) * | 1917-02-20 | 1918-04-16 | Albert Westlake | Mouth-tablet. |
| US1263888A (en) * | 1918-01-10 | 1918-04-23 | J T Vail | Wave-motor. |
| US2887437A (en) | 1956-08-22 | 1959-05-19 | Pfizer & Co C | Palatable vitamin tablet containing an amino acid |
| US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
| US3042531A (en) | 1959-12-09 | 1962-07-03 | Leslie Salt Company | Method of making a compressed tablet |
| US3577490A (en) * | 1967-10-02 | 1971-05-04 | Miles Lab | Effervescent tablet and process for making same |
| GB1212704A (en) | 1967-11-21 | 1970-11-18 | Prodotti Antibiotici Spa | Vaginal suppositories |
| US3888976A (en) * | 1972-09-21 | 1975-06-10 | William P Mlkvy | Zinc and strontium ion containing effervescent mouthwash tablet |
| NL7302521A (en) | 1973-02-23 | 1974-08-27 | Foaming, effervescent capsules - contg. therapeutic agents for rectal and vaginal use | |
| US3962417A (en) * | 1974-03-27 | 1976-06-08 | Howell Charles J | Dentifrice |
| JPS5157813A (en) * | 1974-11-14 | 1976-05-20 | Sankyo Co | Ll dooba mataha sonojudotaiseizaino seiho |
| US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4147768A (en) * | 1976-09-13 | 1979-04-03 | Interx Research Corporation | Enteric coated digoxin and therapeutic use thereof |
| US4370160A (en) | 1978-06-27 | 1983-01-25 | Dow Corning Corporation | Process for preparing silicone microparticles |
| US4187286A (en) * | 1979-01-02 | 1980-02-05 | G&W Laboratories, Inc. | Contraceptive suppository |
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| JPS58152809A (ja) * | 1982-03-05 | 1983-09-10 | Eisai Co Ltd | 安定な発泡性「膣」坐剤 |
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| US4493848A (en) * | 1983-07-14 | 1985-01-15 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
| US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
| GB8410290D0 (en) * | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
| US4613497A (en) * | 1984-02-29 | 1986-09-23 | Health Products Development, Inc. | Dry, water-foamable pharmaceutical compositions |
| US4725427A (en) * | 1984-03-13 | 1988-02-16 | Albion International, Inc. | Effervescent vitamin-mineral granule preparation |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| GB8421226D0 (en) * | 1984-08-21 | 1984-09-26 | Int Conferences Ab | Tooth cleaning tablet |
| US4639368A (en) * | 1984-08-23 | 1987-01-27 | Farmacon Research Corporation | Chewing gum containing a medicament and taste maskers |
| GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4756710A (en) | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US4671953A (en) | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US4687662A (en) * | 1985-08-30 | 1987-08-18 | Warner-Lambert Company | Therapeutic effervescent composition |
| US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
| IT1209667B (it) * | 1985-11-12 | 1989-08-30 | Zambon Spa | Composizione effeverscente adattivita' analgesica. |
| US4876039A (en) | 1986-11-04 | 1989-10-24 | Dow Corning Corporation | Process for preparing silicone microparticles cured by a Michael addition reaction |
| IE873172L (en) | 1986-12-29 | 1988-06-29 | Harvard College | Continuous process for producing a comestible tablet |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2633181B1 (fr) | 1988-06-24 | 1992-01-10 | Glaxo Lab Sa | Composition pharmaceutique a base de ranitidine et son procede de preparation |
| GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
| US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
| US5135752A (en) * | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
| DE3838431A1 (de) * | 1988-11-12 | 1990-05-17 | Bayer Ag | Ibuprofen-brausezubereitungen |
| US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| US5002771A (en) * | 1989-02-06 | 1991-03-26 | Rorer Pharmaceutical Corp. | Calcitonin suppository formulations |
| GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
| TW212139B (https=) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| ATE141511T1 (de) * | 1991-04-15 | 1996-09-15 | Applied Microbiology Inc | Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden. |
| US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| IT1251114B (it) | 1991-07-26 | 1995-05-04 | Farcon Ag | Forme farmaceutiche antivirali per applicazione vaginale |
| DE4139883A1 (de) | 1991-11-29 | 1993-06-03 | Michael Prof Dr Dittgen | Verfahren zur herstellung bioadhaesiver arzneimittel |
| IT1253711B (it) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
| ATE216577T1 (de) * | 1992-01-29 | 2002-05-15 | Takeda Chemical Industries Ltd | Schnellösliche tablette und ihre herstellung |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| US5851553A (en) | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5635210A (en) | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
| US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| JP3021661B2 (ja) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| EP0788346B9 (en) * | 1994-03-18 | 2007-02-14 | Supernus Pharmaceuticals, Inc. | Emulsified drug delivery systems |
| CA2187023A1 (en) * | 1994-04-13 | 1995-10-26 | Steven Andrew Giannos | Temporally controlled drug delivery systems |
| US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5550861A (en) * | 1994-09-27 | 1996-08-27 | Novalink Technologies, Inc. | Modular PCMCIA modem and pager |
| CA2160423A1 (en) * | 1994-11-02 | 1996-05-03 | Hemant N. Joshi | Salts of nefazodone having improved dissolution rates |
| FR2729858B1 (fr) | 1995-01-30 | 1997-04-18 | Mission Soc Civ | Composition effervescente a base de polyvinylpyrrolidone iodee et utilisation pour la desinfection |
| FR2732217B1 (fr) | 1995-03-29 | 1997-06-06 | Hesnard Xavier | Forme d'administration solide a usage oral |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| GB9510830D0 (en) * | 1995-05-27 | 1995-07-19 | Zeneca Ltd | Proteins |
| US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| CA2218370C (en) | 1995-07-31 | 2006-10-03 | Gerhard Gergely | Chewable tablet with effervescent action |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| JPH11504944A (ja) * | 1995-11-06 | 1999-05-11 | サマーセット・ファーマシューティカルズ・インコーポレイテッド | セレギリンの舌下およびバッカル投与 |
| GB9523136D0 (en) * | 1995-11-11 | 1996-01-10 | Procter & Gamble | Silicone-containing powders |
| GB2307857B (en) | 1995-12-04 | 1999-01-27 | Euro Celtique Sa | An effervescent formulation |
| US5958455A (en) * | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
| DE19606151C2 (de) * | 1996-02-20 | 1999-05-12 | Losan Pharma Gmbh | Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben |
| US5646151A (en) * | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| DE19618543C2 (de) * | 1996-05-08 | 1998-07-02 | Ivoclar Ag | Polymerisationsgerät |
| EP0939624B1 (en) | 1996-05-17 | 2003-12-17 | Merck & Co., Inc. | Effervescent bisphosphonate formulation |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
| US20010006677A1 (en) * | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
| PT1015352E (pt) * | 1997-04-01 | 2007-09-24 | Cima Labs Inc | ''embalagem alveolar e comprimidos embalados'' |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
| DE59706616D1 (de) * | 1997-10-27 | 2002-04-18 | Gergely Gerhard | Brausezubereitung mit Pflanzenextrakt |
| US6326360B1 (en) * | 1998-03-11 | 2001-12-04 | Grelan Pharmaceuticals Co., Ltd. | Bubbling enteric coated preparations |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6576250B1 (en) * | 1998-03-27 | 2003-06-10 | Cima Labs Inc. | Pharmaceutical compositions for rectal and vaginal administration |
| DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
| US6368625B1 (en) * | 1998-08-12 | 2002-04-09 | Cima Labs Inc. | Orally disintegrable tablet forming a viscous slurry |
| SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| SE9803239D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6680071B1 (en) | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| US6210699B1 (en) * | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6326384B1 (en) * | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| WO2002045713A2 (en) * | 2000-12-04 | 2002-06-13 | Sepracor, Inc. | Orally-bioavailable formulations of fentanyl and congeners thereof |
| US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| US6713470B2 (en) * | 2002-01-22 | 2004-03-30 | Ml Laboratories Plc | Method of treatment |
| NZ541167A (en) | 2003-01-31 | 2008-07-31 | Orexo Ab | A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water |
| US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
| US20070036853A1 (en) * | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US7862833B2 (en) * | 2003-12-31 | 2011-01-04 | Cima Labs, Inc. | Effervescent oral opiate dosage forms and methods of administering opiates |
| CN102078310B (zh) | 2003-12-31 | 2013-01-23 | 奇马实验室公司 | 大体线性的泡腾口服芬太尼剂型和施用方法 |
| WO2005065317A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| TWI387466B (zh) | 2004-10-04 | 2013-03-01 | Cima Labs Inc | 一般線型起泡的口服吩坦尼（ｆｅｎｔａｎｙｌ）劑型及投藥方法 |
-
2004
- 2004-12-30 CN CN2011100059711A patent/CN102078310B/zh not_active Expired - Lifetime
- 2004-12-30 ME MEP-2011-87A patent/ME01300B/me unknown
- 2004-12-30 AT AT04815716T patent/ATE498395T1/de active
- 2004-12-30 CA CA2548915A patent/CA2548915C/en not_active Expired - Lifetime
- 2004-12-30 EP EP04815716A patent/EP1708686B1/en not_active Expired - Lifetime
- 2004-12-30 DK DK04815716.8T patent/DK1708686T3/da active
- 2004-12-30 US US11/026,132 patent/US7862832B2/en active Active
- 2004-12-30 EA EA200601253A patent/EA010826B1/ru not_active IP Right Cessation
- 2004-12-30 US US11/026,327 patent/US20050142197A1/en not_active Abandoned
- 2004-12-30 BR BRPI0418228A patent/BRPI0418228B8/pt not_active IP Right Cessation
- 2004-12-30 PL PL04815716T patent/PL1708686T3/pl unknown
- 2004-12-30 WO PCT/US2004/043703 patent/WO2005065319A2/en not_active Ceased
- 2004-12-30 HR HR20110336T patent/HRP20110336T1/hr unknown
- 2004-12-30 NZ NZ548216A patent/NZ548216A/en not_active IP Right Cessation
- 2004-12-30 KR KR1020067015392A patent/KR101184138B1/ko not_active Expired - Lifetime
- 2004-12-30 RS RS20110186A patent/RS51713B/sr unknown
- 2004-12-30 JP JP2006547499A patent/JP2007517054A/ja not_active Withdrawn
- 2004-12-30 AU AU2004311880A patent/AU2004311880B2/en active Active
- 2004-12-30 DE DE602004031462T patent/DE602004031462D1/de not_active Expired - Lifetime
- 2004-12-30 PT PT04815716T patent/PT1708686E/pt unknown
-
2006
- 2006-06-20 IL IL176449A patent/IL176449A/en active IP Right Grant
- 2006-07-25 NO NO20063430A patent/NO338714B1/no unknown
-
2010
- 2010-11-29 US US12/955,229 patent/US8092832B2/en not_active Expired - Lifetime
-
2011
- 2011-05-16 CY CY20111100466T patent/CY1111458T1/el unknown
-
2013
- 2013-02-07 JP JP2013022495A patent/JP5685610B2/ja not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078310B (zh) | 大体线性的泡腾口服芬太尼剂型和施用方法 | |
| US8119158B2 (en) | Effervescent oral fentanyl dosage form and methods of administering fentanyl | |
| US8298577B2 (en) | Effervescent oral opiate dosage forms and methods of administering opiates | |
| US20070036853A1 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| TWI387466B (zh) | 一般線型起泡的口服吩坦尼（ｆｅｎｔａｎｙｌ）劑型及投藥方法 | |
| CN1901890B (zh) | 大体线性的泡腾口服芬太尼剂型和施用方法 | |
| HK1100480B (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| MXPA06007449A (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| HK1100166B (en) | Effervescent oral opiate dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130123 |